Company: BDRX
Filing Date: 2025-07-18
Form Type: 424B3
Source: 0001214659-25-010634
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-07-18
Form: 424B3
Chunk 2
---
acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases
with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing
ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the
"Ratio Change"). The effective date of the Ratio Change is expected to be July 31, 2025.

Pursuant to the Ratio Change, ADR holders will
be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive one (1) new ADR (New CUSIP: 59564R880) for every
ten (10) old ADRs (Old CUSIP: 59564R807). No fractional ADRs will be allocated. The aggregate fractions, if any, will be sold and the
net proceeds will be distributed to the entitled ADR holder. The Company's Depositary, JP Morgan Chase Bank, N.A. will contact ADR holders
and arrange for the exchange of their existing ADRs for new ADRs.

For ADR holders, the Ratio Change will have the
same effect as a one-for-ten reverse ADR split. The ordinary shares of Biodexa will not be affected by this change.

The Ratio Change is aimed to bring the price of
the Company’s ADRs into compliance with the Nasdaq $1.00 minimum bid price per share requirement, although Biodexa can
give no assurance that the Ratio Change will be effective in achieving this goal.

Forward-Looking Statements

Certain statements in this announcement may constitute
“forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements
are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future
events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution
you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance
or achievements expressed or implied by such forward-looking statements. All statements contained in this announcement that do not relate
to matters of historical fact should be